160 related articles for article (PubMed ID: 37373240)
21. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract][Full Text] [Related]
22. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
23. Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.
Zhang HQ; Li MH; Gao P; Lan PH; Fan B; Xiao X; Lu YJ; Chen GJ; Wang Z
Orthop Surg; 2016 May; 8(2):129-38. PubMed ID: 27384721
[TBL] [Abstract][Full Text] [Related]
24. Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.
Yu W; Zhang Z; Min D; Yang Q; Du X; Tang L; Lin F; Sun Y; Zhao H; Zheng S; He A; Li H; Yao Y; Shen Z
Eur J Cancer; 2014 Apr; 50(6):1125-36. PubMed ID: 24565852
[TBL] [Abstract][Full Text] [Related]
25. Experimental Study of Somatic Variants of Osteosarcoma by Whole-Exome Sequencing.
Hou J; Liu G; Zhang P; Wang B; Yan Q; Wu P; Wang C; Yao W
Med Sci Monit; 2020 Mar; 26():e920826. PubMed ID: 32193367
[TBL] [Abstract][Full Text] [Related]
26. Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.
Reimann E; Kõks S; Ho XD; Maasalu K; Märtson A
Hum Genomics; 2014 Dec; 8(1):20. PubMed ID: 25496518
[TBL] [Abstract][Full Text] [Related]
27. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
28. Genomics and the Immune Landscape of Osteosarcoma.
Wu CC; Livingston JA
Adv Exp Med Biol; 2020; 1258():21-36. PubMed ID: 32767232
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
30. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
31. Canine osteosarcoma genome sequencing identifies recurrent mutations in
Gardner HL; Sivaprakasam K; Briones N; Zismann V; Perdigones N; Drenner K; Facista S; Richholt R; Liang W; Aldrich J; Trent JM; Shields PG; Robinson N; Johnson J; Lana S; Houghton P; Fenger J; Lorch G; Janeway KA; London CA; Hendricks WPD
Commun Biol; 2019; 2():266. PubMed ID: 31341965
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
33. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.
Zhang C; Yao C; Li H; Wang G; He X
Int J Clin Exp Pathol; 2014; 7(7):4194-203. PubMed ID: 25120799
[TBL] [Abstract][Full Text] [Related]
35. Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.
Scott MC; Temiz NA; Sarver AE; LaRue RS; Rathe SK; Varshney J; Wolf NK; Moriarity BS; O'Brien TD; Spector LG; Largaespada DA; Modiano JF; Subramanian S; Sarver AL
Cancer Res; 2018 Jan; 78(2):326-337. PubMed ID: 29066513
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue.
Fellenberg J; Krauthoff A; Pollandt K; Delling G; Parsch D
Lab Invest; 2004 Jan; 84(1):113-21. PubMed ID: 14631380
[TBL] [Abstract][Full Text] [Related]
37. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
38. An Exploration of Osteosarcoma Metastasis Diagnostic Markers Based on Tumor-Associated Neutrophils.
Tan S; Chao R
Discov Med; 2023 Jun; 35(176):300-311. PubMed ID: 37272097
[TBL] [Abstract][Full Text] [Related]
39. Identification of 6 gene markers for survival prediction in osteosarcoma cases based on multi-omics analysis.
Li R; Wang G; Wu Z; Lu H; Li G; Sun Q; Cai M
Exp Biol Med (Maywood); 2021 Jul; 246(13):1512-1523. PubMed ID: 33563042
[TBL] [Abstract][Full Text] [Related]
40. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
